Pfizer

Prevention trial studies population 100% genetically predisposed to early-onset Alzheimer’s

Monday, August 6, 2012 07:00 AM

For the first time ever, an experimental drug is being tested to determine whether it can prevent Alzheimer’s disease in a population that has a 100% genetic predisposition for early onset of the disease. The study, to start next year, will be one of only a few being conducted to test prevention treatments for a genetically predestined disease.

More... »

Pfizer releases top-line data from phase III study of tofacitinib in RA

Friday, August 3, 2012 11:24 AM

Pfizer reported today top-line results from ORAL Start (A3921069), a phase III study of the investigational agent tofacitinib, a novel, oral Janus kinase (JAK) inhibitor for the treatment of adults with moderate-to-severe active rheumatoid arthritis (RA).

More... »

Pfizer: endpoints not met in first phase III study of bapineuzumab for Alzheimer’s

Tuesday, July 24, 2012 02:54 PM

Pfizer has announced the co-primary clinical endpoints—change in cognitive and functional performance compared to placebo—were not met in the Janssen Alzheimer Immunotherapy R&D (Janssen AI)-led phase III trial of intravenous (IV) bapineuzumab in patients with mild-to-moderate Alzheimer's disease who carry the ApoE4 (apolipoprotein E epsilon 4) genotype (Study 302). Pfizer and Janssen AI are partners in the Alzheimer's Immunotherapy Program (AIP).

More... »

Conatus Pharmaceuticals appoints Morris as head of biostatistics

Thursday, July 19, 2012 08:16 AM

Conatus Pharmaceuticals, a San Diego-based privately held biopharmaceutical company focused on fibrotic disease and oncology, has appointed Mark F. Morris as head of biostatistics.

More... »

Pappas Ventures names Pat Gage to scientific advisory board

Monday, July 9, 2012 04:56 PM

Pappas Ventures, a life sciences investor based in Durham, N.C., has appointed L. Patrick Gage, PhD, to the company's scientific advisory board.

More... »

Pfizer grants ChemRar Group exclusive license to DPP-IVi T2D candidate

Friday, July 6, 2012 02:47 PM

Pfizer has granted  SatRx , a company belonging to Russian pharmaceutical investment and R&D group  ChemRar Hi-Tech Centre , exclusive development and marketing rights to for its DPP(1)-IVi compound, PF-00734200.

More... »

Pfizer’s Karen Bien elected to board of SAFE-BioPharma

Friday, June 29, 2012 09:57 AM

Karen Bien, director of business technology on Pfizer’s acquisition, collaboration and divestiture team, has been elected to the board of directors of SAFE-BioPharma Association, the strategic non-profit collaboration that developed and manages the global SAFE-BioPharma digital identity and digital signature standard for the life science and healthcare sectors.

More... »

Seven global biopharmas form neuroscience consortium

Wednesday, June 20, 2012 02:56 PM

Seven global biopharmaceutical companies have formed the Massachusetts Neuroscience Consortium, which will fund pre-clinical neuroscience at Massachusetts academic and research institutions. Participants include Abbott, Biogen Idec, EMD Serono, Janssen Research & Development, Merck, Pfizer and Sunovion Pharmaceuticals.

More... »

Paratek appoints Molnar and Loh to senior positions

Thursday, May 24, 2012 09:00 AM

Paratek Pharmaceuticals of Boston, Mass., has named Dennis Molnar as director, president and CEO, and Evan Loh, MD, as chief medical officer and chairman of the board of directors.  

More... »

Medivir appoints Juserius commercial executive vice president

Thursday, May 17, 2012 10:44 AM

Medivir, a Stockholm-based specialty pharmaceutical company focused on infectious diseases, has appointed Henric Juserius to head the company's commercial activities.

More... »